Compass Therapeutics Announces Upcoming Poster Presentation at the 39th Society for Immunotherapy of Cancer Annual Meeting
Compass Therapeutics (Nasdaq: CMPX), a clinical-stage oncology-focused biopharmaceutical company, announced the acceptance of an abstract for poster presentation at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting. The meeting will be held from November 8–10, 2024, in Houston, TX.
The poster presentation, titled 'Pharmacodynamic and Response Biomarkers in the Monotherapy Arm of a Phase 1 Trial of CTX-471, a Novel Anti-CD137 Agonist Antibody', will be presented on Friday, November 8, 2024, from 9:00 AM to 7:00 PM CDT in Exhibit Halls AB. The presentation materials will be available on the company's website after the presentation concludes.
Compass Therapeutics (Nasdaq: CMPX), un'azienda biofarmaceutica in fase clinica focalizzata sull'oncologia, ha annunciato l'accettazione di un abstract per la presentazione di un poster al 39° Congresso Annuale della Società per l'Immunoterapia del Cancro (SITC). Il congresso si svolgerà dal 8 al 10 novembre 2024 a Houston, TX.
La presentazione del poster, intitolata 'Biomarcatori Farmacodinamici e di Risposta nell'Armata di Monoterapia di uno Studio di Fase 1 di CTX-471, un Nuovo Anticorpo Agonista Anti-CD137', sarà presentata venerdì 8 novembre 2024, dalle 9:00 alle 19:00 CDT, nelle Sale Espositive AB. I materiali della presentazione saranno disponibili sul sito web dell'azienda dopo il termine della presentazione.
Compass Therapeutics (Nasdaq: CMPX), una compañía biofarmacéutica enfocada en oncología en fase clínica, anunció la aceptación de un resumen para la presentación de un póster en el 39.º Congreso Anual de la Sociedad para la Inmunoterapia del Cáncer (SITC). El congreso se llevará a cabo del 8 al 10 de noviembre de 2024 en Houston, TX.
La presentación del póster, titulada 'Biomarcadores Farmacodinámicos y de Respuesta en el Brazo de Monoterapia de un Ensayo de Fase 1 de CTX-471, un Nuevo Anticuerpo Agonista Anti-CD137', se presentará el viernes 8 de noviembre de 2024, de 9:00 AM a 7:00 PM CDT en los Salones de Exposición AB. Los materiales de la presentación estarán disponibles en el sitio web de la compañía después de que se concluya la presentación.
Compass Therapeutics (Nasdaq: CMPX), 임상 단계의 종양학 중심 생물 제약 회사가 제39회 암 면역 치료 학회(SITC) 연례 회의에서 포스터 발표 초록을 수락했다고 발표했습니다. 이 회의는 2024년 11월 8일부터 10일까지 텍사스주 휴스턴에서 열릴 예정입니다.
포스터 발표 제목은 'CTX-471의 1상 시험 단독 요법군의 약리역학 및 반응 바이오마커'이며, 2024년 11월 8일 금요일 오전 9시부터 오후 7시까지 CDT로 전시관 AB에서 발표됩니다. 발표 자료는 발표가 완료된 후 회사 웹사이트에서 확인할 수 있습니다.
Compass Therapeutics (Nasdaq: CMPX), une société biopharmaceutique en phase clinique axée sur l'oncologie, a annoncé l'acceptation d'un résumé pour la présentation d'un poster lors du 39e Congrès Annuel de la Société pour l'Immunothérapie du Cancer (SITC). Le congrès se déroulera du 8 au 10 novembre 2024 à Houston, TX.
La présentation du poster, intitulée 'Biomarqueurs Pharmacodynamiques et de Réponse dans le Bras de Monothérapie d'un Essai de Phase 1 de CTX-471, un Nouvel Anticorps Agoniste Anti-CD137', sera présentée le vendredi 8 novembre 2024, de 9h00 à 19h00 CDT dans les Salles d'Exposition AB. Les matériaux de la présentation seront disponibles sur le site Web de l'entreprise après la présentation.
Compass Therapeutics (Nasdaq: CMPX), ein biopharmazeutisches Unternehmen in der klinischen Phase mit Schwerpunkt auf Onkologie, gab die Annahme eines Abstracts für die Posterpräsentation auf dem 39. Jahresmeeting der Gesellschaft für Immuntherapie von Krebs (SITC) bekannt. Das Meeting findet vom 8. bis 10. November 2024 in Houston, TX, statt.
Die Posterpräsentation mit dem Titel 'Pharmakodynamische und Respons-Biomarker im Monotherapie-Arm einer Phase-1-Studie zu CTX-471, einem neuartigen Anti-CD137 Agonisten-Antikörper' wird am Freitag, dem 8. November 2024, von 9:00 bis 19:00 Uhr CDT in den Ausstellungsräumen AB präsentiert. Die Präsentationsmaterialien werden nach Abschluss der Präsentation auf der Website des Unternehmens verfügbar sein.
- Acceptance of abstract for poster presentation at a major oncology conference
- Ongoing development of CTX-471, a novel anti-CD137 agonist antibody
- None.
BOSTON, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced the acceptance of an abstract for poster presentation at the upcoming 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting, being held from November 8–10, 2024 at the George R. Brown Convention Center in Houston, TX.
Presentation Details:
| Poster Title: | Pharmacodynamic and Response Biomarkers in the Monotherapy Arm of a Phase 1 Trial of CTX-471, a Novel Anti-CD137 Agonist Antibody | |
| Authors: | Kris Sachsenmeier, Niharika Mettu, Martin Gutierrez, Jeffery Edenfield, Seth Rosen, Minal Barve, Karin Herrera, Natalie Warholic, Diana Albu, Alberto Visintin, Thomas Schuetz, Tanner Johanns | |
| Abstract Number: | 679 | |
| Date & Time: | Friday, November 8, 2024, 9:00 AM – 7:00 PM CDT | |
| Location: | Exhibit Halls AB | |
A copy of the presentation materials can be accessed on the News & Events section under “Presentations” of the Company’s website at www.compasstherapeutics.com once the presentation has concluded.
About Compass Therapeutics
Compass Therapeutics, Inc. is a clinical-stage oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. Compass’s scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. The company pipeline of novel product candidates is designed to target multiple critical biological pathways required for an effective anti-tumor response. These include modulation of the microvasculature via angiogenesis-targeted agents, induction of a potent immune response via activators on effector cells in the tumor microenvironment, and alleviation of immunosuppressive mechanisms used by tumors to evade immune surveillance. Compass plans to advance its product candidates through clinical development as both standalone therapies and in combination with proprietary pipeline antibodies based on supportive clinical and nonclinical data. The company was founded in 2014 and is headquartered in Boston, Massachusetts. For more information, visit the Compass Therapeutics website at https://www.compasstherapeutics.com.
Forward-Looking Statements
This press release contains forward-looking statements. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, statements regarding Compass’s product candidates, including their development and clinical trial milestones such as the expected trial design, timing of enrollment, patient dosing and data readouts, regulatory plans with respect to Compass’s product candidates and the therapeutic potential thereof. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, Compass’s ability to raise the additional funding it will need to continue to pursue its business and product development plans, the inherent uncertainties associated with developing product candidates and operating as a development stage company, Compass’s ability to identify additional product candidates for development, Compass’s ability to develop, complete clinical trials for, obtain approvals for and commercialize any of its product candidates, competition in the industry in which Compass operates and market conditions. These forward-looking statements are made as of the date of this press release, and Compass assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents Compass files with the U.S. Securities and Exchange Commission (SEC) available at www.sec.gov, including without limitation Compass’s latest Annual Report on Form 10-K, Quarterly Report on Form 10-Q and subsequent filings with the SEC.
Investor Contact
ir@compasstherapeutics.com
Media Contact
Anna Gifford, Senior Manager of Communications
media@compasstherapeutics.com
617-500-8099
FAQ
When and where will Compass Therapeutics (CMPX) present at the SITC Annual Meeting in 2024?
What is the title of Compass Therapeutics' (CMPX) poster presentation at SITC 2024?
Where can investors find Compass Therapeutics' (CMPX) SITC 2024 presentation materials?
